Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 4
2005 2
2006 6
2007 11
2008 3
2009 6
2010 7
2011 5
2012 5
2013 5
2014 4
2015 3
2016 1
2017 3
2018 4
2019 9
2020 9
2021 16
2022 16
2023 10
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

125 results

Results by year

Filters applied: . Clear all
Page 1
Transmissible SARS-CoV-2 variants with resistance to clinical protease inhibitors.
Moghadasi SA, Heilmann E, Khalil AM, Nnabuife C, Kearns FL, Ye C, Moraes SN, Costacurta F, Esler MA, Aihara H, von Laer D, Martinez-Sobrido L, Palzkill T, Amaro RE, Harris RS. Moghadasi SA, et al. Among authors: von laer d. Sci Adv. 2023 Mar 29;9(13):eade8778. doi: 10.1126/sciadv.ade8778. Epub 2023 Mar 29. Sci Adv. 2023. PMID: 36989354 Free PMC article.
SARS-CoV-2 3CLpro mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376.
Heilmann E, Costacurta F, Moghadasi SA, Ye C, Pavan M, Bassani D, Volland A, Ascher C, Weiss AKH, Bante D, Harris RS, Moro S, Rupp B, Martinez-Sobrido L, von Laer D. Heilmann E, et al. Among authors: von laer d. Sci Transl Med. 2023 Jan 11;15(678):eabq7360. doi: 10.1126/scitranslmed.abq7360. Epub 2023 Jan 11. Sci Transl Med. 2023. PMID: 36194133 Free PMC article.
A comprehensive study of SARS-CoV-2 main protease (Mpro) inhibitor-resistant mutants selected in a VSV-based system.
Costacurta F, Dodaro A, Bante D, Schöppe H, Sprenger B, Moghadasi SA, Fleischmann J, Pavan M, Bassani D, Menin S, Rauch S, Krismer L, Sauerwein A, Heberle A, Rabensteiner T, Ho J, Harris RS, Stefan E, Schneider R, Kaserer T, Moro S, von Laer D, Heilmann E. Costacurta F, et al. Among authors: von laer d. bioRxiv [Preprint]. 2023 Oct 4:2023.09.22.558628. doi: 10.1101/2023.09.22.558628. bioRxiv. 2023. PMID: 37808638 Free PMC article. Preprint.
Comparison of Four SARS-CoV-2 Neutralization Assays.
Riepler L, Rössler A, Falch A, Volland A, Borena W, von Laer D, Kimpel J. Riepler L, et al. Among authors: von laer d. Vaccines (Basel). 2020 Dec 28;9(1):13. doi: 10.3390/vaccines9010013. Vaccines (Basel). 2020. PMID: 33379160 Free PMC article.
C peptides as entry inhibitors for gene therapy.
Egerer L, Kiem HP, von Laer D. Egerer L, et al. Among authors: von laer d. Adv Exp Med Biol. 2015;848:191-209. doi: 10.1007/978-1-4939-2432-5_10. Adv Exp Med Biol. 2015. PMID: 25757622 Review.
Heterologous Prime-Boost Vaccination with a Peptide-Based Vaccine and Viral Vector Reshapes Dendritic Cell, CD4+ and CD8+ T Cell Phenotypes to Improve the Antitumor Therapeutic Effect.
Hofer T, Rossi M, Carboni S, Di Berardino Besson W, von Laer D, Wollmann G, Derouazi M, Santiago-Raber ML. Hofer T, et al. Among authors: von laer d. Cancers (Basel). 2021 Dec 3;13(23):6107. doi: 10.3390/cancers13236107. Cancers (Basel). 2021. PMID: 34885215 Free PMC article.
Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection.
Rössler A, Knabl L, von Laer D, Kimpel J. Rössler A, et al. Among authors: von laer d. N Engl J Med. 2022 May 5;386(18):1764-1766. doi: 10.1056/NEJMc2201607. Epub 2022 Mar 23. N Engl J Med. 2022. PMID: 35320661 Free PMC article. No abstract available.
125 results